Linked Life Data

11926130

Source:http://linkedlifedata.com/resource/pubmed/id/11926130

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2002-4-2
pubmed:abstractText
Peptides make up only a fraction of therapeutically beneficial pharmaceutical molecules that are either in clinical testing or in the market. Despite the initially low number and impact of peptides on therapeutics, their potential has just intensified with new developments in modifications, stability, delivery and preclinical success. With the completion of the human genome sequence and developments in the proteomics field, peptides are emerging as important molecules for cancer therapy. Several peptides with exciting preclinical results have now entered into clinical trial for the treatment of human cancers. In this review, some of the recent advances in peptide-based cancer therapeutics will be discussed.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1367-6733
pubmed:author
pubmed:issnType
Print
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
245-50
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Recent developments in peptide-based cancer therapeutics.
pubmed:affiliation
ChemGenex Therapeutics Inc, Molecular Biology and Genomics, 3475 M Edison Way, Menlo Park, CA 94025, USA. asehgal@chemgenex.com
pubmed:publicationType
Journal Article, Review